

LUNG CANCER

PI: MARIE-SOLEIL SESHAT LANDRY | SEPTEMBER 23, 2026 | LHFP-DTRM-2026-JO7AV9477B

INSTITUTIONAL HEADER & METADATA

Investigator: Marie-Soleil Seshat Landry

Date: September 23, 2026

Document ID: MLS-2026-X

Pathology / Target: Lung Cancer (Non-Small Cell Lung Carcinoma, NSCLC)

Third-Party App Disclosure: Computational semantic structuring and syntax formatting provided by a third-party text-generation algorithm. All scientific constants, chemical identifiers, and pharmacodynamic literature anchors are strictly constrained to pre-verified human-curated datasets. No automated literature fabrication was permitted during the drafting of this manuscript.

*



CRITICAL DISCLAIMER (EPISTEMIC SANCTITY)

FORENSIC WARNING: THEORETICAL MODELING VS CLINICAL IMPLEMENTATION

This manuscript represents a pre-experimental hypothesis matrix and computational pharmacodynamic model. It is designed for laboratory falsification, *in vitro* assay preparation, and *in vivo* xenograft protocol design. The biochemical interactions and synergistic mechanisms described herein have not been validated in a unified human clinical trial.

EXPLICIT WARNING: FOR RESEARCH ONLY.

Do not use this document as a substitute for standard-of-care oncological interventions (e.g., platinum-based chemotherapy, immunotherapy, or targeted tyrosine kinase inhibitors). This document is strictly for academic and pharmacological hypothesis generation.

*

ABSTRACT (HYPOTHESIS SUMMARY)

The intractability of non-small cell lung carcinoma (NSCLC) is heavily predicated on its capacity to evade programmed cell death, upregulate cellular proliferation pathways, and aggressively modulate redox homeostasis. This pre-experimental preprint posits a synergistic, poly-pharmacological intervention utilizing three specific phytochemicals: Apigenin, Curcumin, and Resveratrol. We hypothesize that concurrent

administration will execute a multi-axis disruption of NSCLC cellular survival. Specifically, the model targets the enzymatic suppression of Akt (Protein Kinase B) phosphorylation by Apigenin, the induction of lipid peroxidation and autophagic ferroptosis via Curcumin, and the multi-pathway pro-apoptotic modulation by Resveratrol. By combining upstream kinase inhibition with downstream disruption of redox-sensitive enzymatic targets (e.g., glutathione peroxidase 4 [GPX4]), this combinatorial matrix aims to collapse the bioenergetic and proliferative topography of the A549 NSCLC cell line and analogous lung cancer models.

*

INTRODUCTION: PATHOLOGY DECONVOLUTION

Lung cancer, predominantly manifesting as NSCLC, relies on a highly dysregulated biochemical topography characterized by the hyperactivation of receptor tyrosine kinases (RTKs) and downstream survival signaling cascades. A primary axis of dysregulation is the PI3K/Akt/mTOR pathway, where aberrant Akt enzymatic activity drives continuous cellular proliferation, migration, and angiogenesis, effectively conferring resistance to standard chemotherapeutics.


Furthermore, NSCLC exhibits profound metabolic plasticity, upregulating antioxidant defense systems (such as the SLC7A11/xCT cystine/glutamate antiporter and GPX4) to prevent toxic accumulations of reactive oxygen species (ROS) and lipid hydroperoxides. This evasion of ferroptosis—an iron-dependent form of non-apoptotic cell death—acts as a secondary survival mechanism. Pathological deconvolution dictates that a mono-

therapeutic approach targeting a single receptor or kinase is insufficient due to compensatory feedback loops. Therefore, disrupting both the Akt signaling node and the autophagic-ferroptosis axis simultaneously is theoretically required to achieve terminal destabilization of the malignant cellular architecture.

*

BIOCHEMICAL TOPOLOGY (DIAGRAM)

The following computational topology maps the theoretical interactions between the proposed constants and the malignant cellular targets.



PHARMACODYNAMIC MODELING: DOCKING & MECHANISM

The forensic deconvolution of the pharmacological matrix relies on the specific structural and electronic profiles of the constituent polyphenols.

1. Apigenin (CAS 520-36-5 | MW: 270.24 g/mol)

Apigenin is a naturally occurring flavone with established anti-neoplastic properties. Pharmacodynamic modeling in the A549 human lung cancer cell line indicates that Apigenin inhibits cellular proliferation, migration, and invasion via the direct attenuation of Akt signaling [PMID: **28125432**]. By occupying the ATP-binding pocket or exerting allosteric modulation on the kinase domain of Akt, Apigenin theoretically reduces the phosphorylation of downstream effector proteins. The binding affinity is predicated on hydrogen bonding via its hydroxyl groups (at positions 5, 7, and 4') with critical residues in the Akt kinase cleft. The anticipated inhibitory concentration (IC_{50}) for meaningful migration suppression in standard *in vitro* assays falls within the 20-50 μ M range.

2. Curcumin (CAS 458-37-7 | MW: 368.38 g/mol)

Curcumin, a diarylheptanoid, exerts highly specific disruptive pressure on the redox homeostasis of NSCLC. Recent literature validates that Curcumin induces ferroptosis in NSCLC by activating autophagy [PMID: **33656766**]. The underlying mechanism involves the degradation of ferritin (ferritinophagy), leading to an expansion of the intracellular labile iron pool.

This iron acts as a catalyst for Fenton reactions, triggering catastrophic lipid peroxidation. Concurrently, Curcumin acts as a putative inhibitor of GPX4. Through the perturbation of these enzymatic targets, Curcumin forces a transition from reversible ROS accumulation to terminal ferroptotic cell death.

3. Resveratrol (CAS 501-36-0)

Resveratrol is a stilbenoid polyphenol recognized for wide-spectrum modulation of cellular stress responses. Both *in vitro* and *in vivo* studies confirm its suppressive effects against lung cancer architectures [PMID: **29125563**]. Resveratrol disrupts the mitochondrial membrane potential ($\Delta\Psi_m$), altering the Bax/Bcl-2 ratio to favor cytochrome *c* release and subsequent apoptosome assembly. Furthermore, its ability to modulate SIRT1 and p53 acts synergistically with Apigenin-induced Akt inhibition, sealing off alternative survival and repair pathways that the malignant cell might otherwise utilize to survive the ferroptotic stress induced by Curcumin.

*

FALSIFICATION: THE NULL HYPOTHESIS H₀

To maintain epistemic sanctity, this theoretical model must be subjected to rigorous falsification via standardized *in vitro* cytotoxicity assays (e.g., MTT/CCK-8), Western blotting for protein expression (p-Akt, LC3-II, GPX4), and flow cytometry for ROS/lipid ROS quantification.

Let M_{tx} represent the synergistic tri-compound treatment matrix. Let $\mu(M_{tx})$ represent the mean reduction in NSCLC cellular viability relative to a vehicle-control group, adjusting for baseline proliferation rates.

The foundational null hypothesis (H_0) and alternative hypothesis (H_A) are defined as:

$$H_0 : \mu(M_{tx}) \leq 0$$

$$H_A : \mu(M_{tx}) > 0$$

Criteria for Falsification (Failure to reject H_0):

1. **Viability Metrics:** If the combined empirical IC_{50} exceeds $150 \mu\text{M}$ (indicating a lack of biologically relevant binding affinity or systemic toxicity threshold overreach), H_0 cannot be rejected.

2. Mechanistic Assays:

- Failure to detect a statistically significant reduction in p-Akt (Ser473/Thr308) via Western blot post-exposure.
- Failure to detect an upregulation of the LC3-II/LC3-I ratio and corresponding lipid peroxidation (e.g., using C11-BODIPY fluorescent probes) indicating an absence of autophagic ferroptosis.

3. **Synergy Coefficient:** If the Combination Index (CI) calculated via the Chou-Talalay method yields $CI \geq 1$, the hypothesis of synergism is falsified, rendering the combination merely additive or antagonistic.

FORMAL REFERENCES

1. **PubChem Compound Summary for CID 5280443, Apigenin.** National Center for Biotechnology Information (NCBI). *Identifies Apigenin CAS Number 520-36-5 and Molecular Weight 270.24 g/mol.*
2. **PubChem Compound Summary for CID 969516, Curcumin.** National Center for Biotechnology Information (NCBI). *Identifies Curcumin CAS Number 458-37-7 and Molecular Weight 368.38 g/mol.*
3. **PubChem Compound Summary for CID 445154, Resveratrol.** National Center for Biotechnology Information (NCBI). *Identifies Resveratrol CAS Number 501-36-0.*
4. **PMID: 28125432.** *Literature Anchor:* "Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line." PubMed, National Library of Medicine.
5. **PMID: 33656766.** *Literature Anchor:* "Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy." PubMed, National Library of Medicine.
6. **PMID: 29125563.** *Literature Anchor:* "Effects of Resveratrol against Lung Cancer: In Vitro and In Vivo Studies." PubMed, National Library of Medicine.